AustraliaProduct Registration for Medical Devices in Australia
Taevas Global helps medical devices manufacturers achieve TGA registration and enter the Australian market with confidence, speed, and full regulatory compliance. From ARTG inclusion to post-market obligations, we manage every step so you can focus on gro
Six Pillars of Australia Medical Devices Intelligence
Our end-to-end framework covers every dimension of TGA product registration so medical devices companies enter Australia with a complete, defensible market strategy.
Regulatory Pathway Analysis
We map your device against Australia's risk-based classification system under the Therapeutic Goods (Medical Devices) Regulations 2002, identifying whether your product falls into Class I, IIa, IIb, or III. Our team determines the correct ARTG inclusion pathway and highlights any conformity assessment obligations before you invest in submissions.
From Brief to Board-Ready Intelligence
Our structured four-stage engagement transforms your product information and regulatory ambitions into a fully submitted and actively managed TGA registration.
Discovery and Scoping
We begin with a structured intake session to understand your device, intended use, target patient population, and existing regulatory approvals in other markets such as FDA 510(k), CE marking, or PMDA clearance. This session defines the project scope, timelines, and resource requirements.
During discovery we collect your device description, indications for use, manufacturing site details, existing quality management system certifications such as ISO 13485, and any prior regulatory correspondence. We use this information to produce a written scoping document that becomes the foundation of your TGA registration project plan.
Australia Medical Devices Market at a Glance
TGA Alignment with International Standards
Australia's TGA has progressively aligned its medical device framework with IMDRF guidelines and recognises conformity assessments from bodies in the EU, USA, Canada, and Japan, enabling manufacturers with existing approvals to leverage prior work. However, Australian-specific labelling, sponsor requirements, and Essential Principles still require dedicated local compliance steps that cannot be skipped.
Risk-Based Classification System
The TGA classifies medical devices from Class I through to Class III and AIMD based on intended use and risk to the patient, with higher-class devices requiring conformity assessment by a TGA-approved body before ARTG inclusion. Misclassification is one of the most common causes of submission delay, making early regulatory pathway analysis critical for manufacturers new to the Australian market.
Growing Demand for Digital Health and IVD
Australia has seen rapid growth in demand for in vitro diagnostic devices and software as a medical device, driven by telehealth expansion and an ageing population. The TGA has published specific guidance for SaMD under the IMDRF framework and has a dedicated IVD regulatory pathway, creating distinct opportunities for manufacturers in these segments.
Mandatory Australian Sponsor Requirement
Unlike some markets where foreign manufacturers can self-register, Australia requires every medical device on the ARTG to have an Australian sponsor who is legally responsible for the product's compliance and post-market obligations. This requirement is a common barrier for international manufacturers who lack a local presence or established distribution partners.
Everything in Your Report
Every Taevas Global Product Registration engagement for Australia delivers a structured set of outputs designed to take your medical device from initial assessment to active ARTG listing.
Regulatory Pathway Report
A written assessment of your device's TGA classification, applicable ARTG pathway, and conformity assessment requirements, with a clear recommendation on the fastest compliant route to market.
Gap Analysis and Remediation Plan
A detailed comparison of your existing technical documentation against TGA Essential Principles, with a prioritised action list, estimated effort, and timeline for each gap identified.
Compiled ARTG Dossier
A complete, TGA-formatted registration dossier including device description, clinical evaluation, Essential Principles checklist, labelling review, and quality system evidence ready for submission.
Regulatory Risk Assessment
An analysis of the key regulatory risks associated with your submission, including potential TGA queries, classification disputes, and clinical evidence challenges, with mitigation strategies for each.
Australian Market Entry Roadmap
A phased market entry plan covering registration milestones, sponsor onboarding, distribution channel considerations, and post-approval compliance obligations specific to the Australian market.
Sponsor Identification and Vetting Report
A shortlist of qualified Australian sponsors or a framework for establishing your own Australian entity, with due diligence notes and recommended contractual provisions for sponsor agreements.
Post-Market Surveillance Plan
A TGA-compliant post-market surveillance plan template calibrated to your device class, covering adverse event reporting thresholds, vigilance timelines, and periodic safety update schedules.
Regulatory Affairs Handover Briefing
A structured briefing document and live session for your internal regulatory or commercial team covering ongoing TGA obligations, renewal timelines, and escalation contacts for post-approval management.
Built for These Situations
International Manufacturer Entering Australia for the First Time
Your device is approved in the US, EU, or another major market and you are now targeting Australia as your next growth market. You have strong clinical data but limited familiarity with TGA requirements, sponsor obligations, and the ARTG inclusion process. Every month of delay has a direct commercial cost.
After Product Registration, Most Clients Move To
Common Questions
Ready to Map Your Australia Opportunity?
Talk to a Taevas Global regulatory specialist today and get a clear, actionable roadmap for achieving TGA registration and building a sustainable medical devices business in Australia.